Abstract
Congenital thrombotic thrombocytopenic purpura (cTTP) is a rare autosomal recessive condition that causes deficiency of the von Willebrand factor (vWF)-cleaving metalloprotease, a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13). Traditionally, cTTP has been managed with plasma infusions, whether in the acute or prophylactic settings; however, there are various limitations and risks associated with this treatment modality. Recombinant ADAMTS13 (rADAMTS13) is the first FDA-approved product for management of cTTP. A phase III study compared rADAMTS13 to standard of care in which patients initially received prophylactic rADAMTS13 or plasma therapy, then crossed over to the alternative therapy. Patients receiving prophylactic rADAMTS13 had no acute cTTP events and lower rates of cTTP manifestations compared to standard of care. This article reviews the pharmacology, pharmacokinetics, efficacy, safety, dosing, administration, and implications for advanced practitioners of rADAMTS13 for the management of cTTP.
References
Alwan, F., Vendramin, C., Liesner, R., Clark, A., Lester, W., Dutt, T., Thomas, W., Gooding, R., Biss, T., Watson, H. G., Cooper, N., Rayment, R., Cranfield, T., van Veen, J. J., Hill, Q. A., Davis, S., Motwani, J., Bhatnagar, N., Priddee, N.,…Scully, M. (2019). Characterization and treatment of congenital thrombotic thrombocytopenic purpura. Blood, 133(15), 1644–1651. https://doi.org/10.1182/blood-2018-11-884700
Asmis, L. M., Serra, A., Krafft, A., Licht, A., Leisinger, E., Henschkowski-Serra, J., Ganter, M. T., Hauptmann, S., Tinguely, M., & Kremer Hovinga, J. A. (2022). Recombinant ADAMTS13 for hereditary thrombotic thrombocytopenic purpura. New England Journal of Medicine, 387(25), 2356–2361. https://doi.org/10.1056/NEJMoa2211113
Choosing Wisely. (2024). Hematology.org. https://www.hematology.org/education/clinicians/guidelines-and-quality-care/choosing-wisely
Dadoun, S., Adam, K., Hensch, L., Boyd, T. K., Ibrahimi, S., George, J. N., Scully, M., & Sukumar, S. (2024). Recombinant ADAMTS13: An effective rescue therapy for acute cTTP during pregnancy. Blood Advances, 8(14), 3718–3720. https://doi.org/10.1182/bloodadvances.2024013265
Gounder, P., & Scully, M. (2024). TTP and pregnancy. British Journal of Haematology, 205(4), 1288–1290. https://doi.org/10.1111/bjh.19723
Grifols Therapeutics LLC. (2022). Koate (Antihemophilic Factor [Human]) package insert. https://www.mykoate.com/pdfs/KOATE%20Prescribing%20Information.pdf
Hollifield, A. L., Arnall, J. R., & Moore, D. C. (2020). Caplacizumab: An anti–von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura. American Journal of Health-System Pharmacy, 77(15), 1201–1207. https://doi.org/10.1093/ajhp/zxaa151
Kremer Hovinga, J. A., & George, J. N. (2019). Hereditary thrombotic thrombocytopenic purpura. New England Journal of Medicine, 381(17), 1653–1662. https://doi.org/10.1056/NEJMra1813013
Peyvandi, F., Mannucci, P. M., Valsecchi, C., Pontiggia, S., Farina, C., & Retzios, A. D. (2013). ADAMTS13 content in plasma-derived factor VIII/von Willebrand factor concentrates. American Journal of Hematology, 88(10), 895–898. https://doi.org/10.1002/ajh.23527
Reutter, J. C., Sanders, K. F., Brecher, M. E., Jones, H. G., & Bandarenko, N. (2001). Incidence of allergic reactions with fresh frozen plasma or cryo-supernatant plasma in the treatment of thrombotic thrombocytopenic purpura. Journal of Clinical Apheresis, 16(3), 134–138. https://doi.org/10.1002/jca.1025
Scully, M., Antun, A., Cataland, S. R., Coppo, P., Dossier, C., Biebuyck, N., Hassenpflug, W. A., Kentouche, K., Knobl, P., Kremer Hovinga, J. A., Lopez-Fernandez, M. F., Matsumoto, M., Ortel, T. L., Windyga, J., Bhattacharya, I., Cronin, M., Li, H., Mellgard, B., Patel, M.,…TTP PPS Investigators. (2024). Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura. New England Journal of Medicine, 390(17), 1584–1596. https://doi.org/10.1056/NEJMoa2314793
Scully, M., Knobl, P., Kentouche, K., Rice, L., Windyga, J., Schneppenheim, R., Kremer Hovinga, J. A., Kajiwara, M., Fujimura, Y., Maggiore, C., Doralt, J., Hibbard, C., Martell, L., & Ewenstein, B. (2017). Recombinant ADAMTS-13: First-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura. Blood, 130(19), 2055–2063. https://doi.org/10.1182/blood-2017-06-788026
Scully, M., Yarranton, H., Liesner, R., Cavenagh, J., Hunt, B., Benjamin, S., Bevan, D., Mackie, I., & Machin, S. (2008). Regional UK TTP registry: Correlation with laboratory ADAMTS13 analysis and clinical features. British Journal of Haematology, 142(5), 819–826. https://doi.org/10.1111/j.1365-2141.2008.07276.x
Sukumar, S., Lammle, B., & Cataland, S. R. (2021). Thrombotic thrombocytopenic purpura: Pathophysiology, diagnosis, and management. Journal of Clinical Medicine, 10(3). https://doi.org/10.3390/jcm10030536
Takeda Pharmaceuticals. (2023). Adzynma (ADAMTS13 Recombinant) package insert. https://content.takeda.com/?contenttype=PI&product=ADZ&language=ENG&country=USA&documentnumber=1
von Krogh, A. S., Quist-Paulsen, P., Waage, A., Langseth, O. O., Thorstensen, K., Brudevold, R., Tjonnfjord, G. E., Largiader, C. R., Lammle, B., & Kremer Hovinga, J. A. (2016). High prevalence of hereditary thrombotic thrombocytopenic purpura in central Norway: From clinical observation to evidence. Journal of Thrombosis and Haemostasis, 14(1), 73–82. https://doi.org/10.1111/jth.13186
